Image

Kieran Gostin

Partner

Kieran Gostin is a Partner at Wilkinson Stekloff. He has represented clients in high-profile matters for more than a decade. Recently, he has represented clients in several major class actions, including obtaining a complete defense verdict in a rare trial of a major consumer class action. Prior to those representations, he spent several years representing Bayer in products liability litigation, including being a member of four trial teams that obtained defense judgments for our client.

Most recently, Kieran was a member of the trial team that secured a groundbreaking victory for Microsoft, defeating the FTC’s efforts to enjoin its $68.79 billion acquisition of Activision Blizzard and winning the second-biggest merger trial in American history. Kieran handled multiple witnesses in the five-day bench trial, following which Judge Jacqueline Scott Corley denied the FTC’s motion for preliminary injunction, finding that the FTC failed to make its case that the acquisition would substantially lessen competition in the gaming industry.

Among his many trial victories was the first jury verdict for Bayer in the Roundup litigation in a Los Angeles Superior Court case involving a boy diagnosed with cancer at age five, on which Kieran advised on all aspects of trial strategy for the defense team. Kieran was also a member of the trial team in a multi-state class action that accused Bayer of using misleading claims to market One A Day multivitamins. Kieran was responsible for arguing legal issues at the trial, as well as cross-examining one of the class representatives. The jury returned a complete defense verdict in less than two hours.

Kieran previously represented Bayer in In re Xarelto (Rivaroxaban) Products Liability Litigation, a nationwide federal MDL proceeding involving over 20,000 lawsuits related to the blood-thinner Xarelto. Kieran was a member of the trial team that won complete defense verdicts in the first two bellwether trials in the MDL and a member of the trial team that won JNOV in the first state court bellwether trial in Philadelphia’s Court of Common Pleas.

In recognition of these successful outcomes, Kieran has received “Rising Star” awards from the National Law Journal and Law360, and “Future Star” from Benchmark Litigation. Lawdragon has named him to its “500 Leading Litigators in America” list.

Before joining the firm, Kieran was a trial attorney in the Federal Programs Branch of the U.S. Department of Justice, where he was the lead attorney in matters challenging the legality of executive agency action, including cases involving challenges to federal healthcare and national security programs.


Education

  • Undergraduate: Georgetown University, B.A., cum laude.
  • Masters: London School of Economics and Political Science, M.Sc., Pass with Merit.
  • Law: Harvard Law School, J.D., cum laude.

Clerkship

  • Judge Thomas L. Ambro, United States Court of Appeals for the Third Circuit
  • Judge Shira A. Scheindlin, United States District Court for the Southern District of New York

Notable Matters

  • Member of the trial team that secured a groundbreaking victory for Microsoft, defeating the FTC’s efforts to enjoin its $68.79 billion acquisition of Activision Blizzard and winning the second-biggest merger trial in American history. Handled multiple witnesses in the five-day bench trial, following which Judge Jacqueline Scott Corley denied the FTC’s motion for preliminary injunction, finding that the FTC failed to make its case that the acquisition would substantially lessen competition in the gaming industry.  The deal closed shortly thereafter.
  • Advised on all aspects of trial strategy for the defense team in Clark v. Monsanto, a trial involving claims that the herbicide Roundup causes Non-Hodgkin Lymphoma. Clark was the fourth case in this mass tort to go to trial; the three previous trials resulted in verdicts against Monsanto ranging from $81 million to over $2 billion. After a single day of deliberation, a jury delivered the first-ever verdict for Monsanto in the Roundup mass tort litigation.
  • Member of trial team that won complete defense verdicts in first two bellwether trials in In re: Xarelto (Rivaroxaban) Products Liability Litigation, a nationwide federal MDL proceeding involving over 20,000 lawsuits related to the blood-thinner Xarelto.
  • Member of trial team that won JNOV in Hartman Janssen, the first state-court bellwether trial involving Xarelto in Philadelphia’s Court of Common Pleas.
  • Represented Forest Laboratories in In re Namenda Direct Purchaser Antitrust Litigation, a certified antitrust class action in the Southern District of New York involving a groundbreaking treatment for dementia in Alzheimer’s patients. Plaintiffs claimed that Forest made an anticompetitive “reverse payment” to settle a generic drug manufacturer’s challenge to Namenda, and that Forest unlawfully tried to effectuate a “hard switch” between a twice-daily and once-daily version of Namenda. Plaintiffs claimed approximately $21 billion in trebled damages; the case settled the night before trial for less than 5% of that amount.
  • Member of trial team in a multi-state class action tried in February 2019 that accused Bayer Corporation of using misleading claims to market One A Day multivitamins. Kieran was responsible for arguing legal issues at the trial, as well as cross examining one of the class representatives. The jury returned a complete defense verdict in less than two hours.
  • Lead attorney for federal government in successful defense of national security program related to the sharing of information about suspicious activities among state, local, and federal law enforcement.
  • Lead attorney for federal government in challenge to constitutionality of the Navy Chaplain Corps’ decision not to commission an officer candidate endorsed by a humanist organization. The Court dismissed all but one of the candidate’s First Amendment, RFRA, and other claims, and the government subsequently entered into a favorable settlement to resolve the dispute.